Skip to content Skip to footer
Subscribe Now

INSIGHTS+

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)
J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)
Shots:   In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…
January 15, 2025
The US FDA New Drug Approvals in December 2024
The US FDA New Drug Approvals in December 2024
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of December 2024      The US FDA has approved a total of 10 new drugs including 4 new molecular entities and 6 biologics leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was BMS’ Opdivo Qvantig…
January 14, 2025
PharmaShots’ Key Highlights of Fourth Quarter 2024
PharmaShots’ Key Highlights of Fourth Quarter 2024
Shots:  The Fourth quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Roche's acquisition of Poseida Therapeutics for ~$1.5B  This quarter also showcased multiple clinical trial results including Pfizer's P-III Study Data of Talzenna + Xtandi to treat mCRPC …
January 13, 2025
J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)
Shots:  The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024  Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion   Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…
January 8, 2025
Key Biosimilars Events of December 2024
Key Biosimilars Events of December 2024
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients A major highlight was the US FDA’s approval of Biocon Biologics’ Yesintek…
January 7, 2025
Key Biosimilars Events of December 2024
Key Biosimilars Events of December 2024
Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        A major highlight was the US FDA’s approval of Biocon Biologics’ Yesintek…
January 7, 2025
Most Viewed Articles of 2024 
2024, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.      Top 20 Medical Device Companies of 2024   Shots:    Bringing innovation and technology to healthcare, the…
January 2, 2025
New Drug Designations - November 2024
New Drug Designations – November 2024
Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, and NMPA   The November 2024 report covers designations granted to 28 drugs and 3 devices, encompassing 9 small molecules, 6 biologics, 7 cell and gene therapies as well as 3 medical devices  Significant trends…
December 31, 2024
Disease of the Month – Dry age-related macular degeneration (dAMD)
Disease of the Month – Dry age-related macular degeneration (dAMD)
Shots:  Dry age-related macular degeneration (dAMD) is a common eye disorder that gradually damages the macula, the central part of the retina, responsible for sharp vision  Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and the role of patient advocacy groups. Additionally, we highlight the key industry…
December 24, 2024
EMA Marketing Authorization of New Drugs in November 2024
EMA Marketing Authorization of New Drugs in November 2024
Shots:    The EMA’s CHMP has granted positive opinions to 3 Biologics and 2 New Chemical Entities in November 2024, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were AbbVie’s Elahere to treat Ovarian Cancer and Pfizer’s Hympavzi for Hemophilia A and B   PharmaShots has compiled a list of…
December 19, 2024
Load more